サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1463113

ギランバレー症候群市場、シェア、規模、動向、産業分析レポート：治療薬別、投与経路別、流通チャネル別、地域別、セグメント別予測、2024年～2032年

Guillain-Barre Syndrome Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, Others); By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 119 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ギランバレー症候群市場、シェア、規模、動向、産業分析レポート：治療薬別、投与経路別、流通チャネル別、地域別、セグメント別予測、2024年～2032年
出版日: 2024年03月24日
発行: Polaris Market Research
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界のギランバレー症候群市場規模は2032年までに9億6,058万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

米国食品医薬品局（USFDA）による医薬品承認促進イニシアチブは、製薬業界における新製品承認の大幅な増加を促進する上で極めて重要な役割を果たしています。このイニシアチブは、革新的な医薬品、特にアンメット・メディカル・ニーズに対応する医薬品の開発と利用を促進することを目的としています。USFDAは規制プロセスを合理化することで、製薬会社が新しい治療法を市場に投入するための、より効率的な道筋を作り出し、最終的に様々な病状の患者に利益をもたらしています。

新製品の承認が急増している注目すべき分野のひとつに、ギラン・バレー症候群（GBS）の市場があります。GBSは、免疫系が末梢神経を攻撃し、筋力低下や重篤な合併症を引き起こす可能性があることを特徴とする稀な神経疾患です。医薬品の承認取得を加速させることが重要視され、GBS領域における研究開発に拍車がかかり、その結果、この疾患特有の課題に対処するための革新的な治療法のイントロダクションが生み出されています。

製薬会社はGBS研究への投資を増やしており、規制当局の合理化されたプロセスを活用して臨床試験を迅速化し、潜在的な治療法をより早く市場に投入しています。このことは、GBS患者に対する治療法の展望を広げただけでなく、より競合的な市場環境を生み出し、治療法のさらなる革新と進歩を促しています。

医薬品承認迅速化イニシアチブの好影響は、FDAが承認したGBS治療薬の数が増加していることからも明らかであり、ヘルスケア専門家に、この課題の多い疾患を管理・治療するための新たな手段を提供しています。製薬業界がこのような迅速承認制度を採用し続けることで、希少疾患治療の情勢が一変する可能性があり、ギラン・バレー症候群のような疾患の患者に希望と転帰の改善をもたらします。

ギラン・バレー症候群市場レポートハイライト

免疫グロブリン点滴製剤は、適用が容易であることから、今後数年間で最も高い成長が見込まれています。

免疫グロブリン静注療法における有効性により、親薬品市場が最大の市場シェアを占める

病院薬局セグメントは、自己免疫症例の増加により、より大きな収益シェアを占めると予測されます。

アジア太平洋地域は、老年人口の存在とこの分野における技術革新により急成長します。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 ギランバレー症候群の世界市場の洞察

  • ギランバレー症候群市場- 流通チャネルスナップショット
  • ギランバレー症候群の市場力学
    • 促進要因と機会
      • ギランバレー症候群の罹患率の上昇
      • ギランバレー症候群のリスク増加
    • 抑制要因と課題
      • 治療に関する認知度の低さが市場の成長を阻害する可能性がある
  • PESTEL分析
  • ギランバレー症候群市場の流通チャネルの動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 ギランバレー症候群の世界市場、治療分野別

  • 主な調査結果
  • イントロダクション
  • 静脈内免疫グロブリン
  • 血漿交換
  • その他

第6章 ギランバレー症候群の世界市場、投与経路別

  • 主な調査結果
  • イントロダクション
  • 経口
  • ペアレンタル

第7章 ギランバレー症候群の世界市場、流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • 小売薬局
  • その他

第8章 世界のギランバレー症候群市場、地域別

  • 主な調査結果
  • イントロダクション
    • ギランバレー症候群市場評価、地域別、2019年～2032年
  • ギランバレー症候群市場-北米
    • 北米：ギランバレー症候群市場、治療分野別、2019年～2032年
    • 北米：ギランバレー症候群市場、流通チャネル別、2019年～2032年
    • 北米：ギランバレー症候群市場、投与経路別、2019年～2032年
    • ギランバレー症候群市場-米国
    • ギランバレー症候群市場- カナダ
  • ギランバレー症候群市場- 欧州
    • 欧州：ギランバレー症候群市場、治療分野別、2019年～2032年
    • 欧州：ギランバレー症候群市場、流通チャネル別、2019年～2032年
    • 欧州：ギランバレー症候群市場、投与経路別、2019年～2032年
    • ギランバレー症候群市場- 英国
    • ギランバレー症候群市場- フランス
    • ギランバレー症候群市場- ドイツ
    • ギランバレー症候群市場- イタリア
    • ギランバレー症候群市場- スペイン
    • ギランバレー症候群市場- オランダ
    • ギランバレー症候群市場- ロシア
  • ギランバレー症候群市場- アジア太平洋
    • アジア太平洋：ギランバレー症候群市場、治療分野別、2019年～2032年
    • アジア太平洋：ギランバレー症候群市場、流通チャネル別、2019年～2032年
    • アジア太平洋：ギランバレー症候群市場、投与経路別、2019年～2032年
    • ギランバレー症候群市場- 中国
    • ギランバレー症候群市場- インド
    • ギランバレー症候群市場- マレーシア
    • ギランバレー症候群市場- 日本
    • ギランバレー症候群市場- インドネシア
    • ギランバレー症候群市場- 韓国
  • ギランバレー症候群市場-中東・アフリカ
    • 中東・アフリカ：ギランバレー症候群市場、治療分野別、2019年～2032年
    • 中東・アフリカ：ギランバレー症候群市場、流通チャネル別、2019年～2032年
    • 中東・アフリカ：ギランバレー症候群市場、投与経路別、2019年～2032年
    • ギランバレー症候群市場- サウジアラビア
    • ギランバレー症候群市場-UAE
    • ギランバレー症候群市場- イスラエル
    • ギランバレー症候群市場- 南アフリカ
  • ギランバレー症候群市場-ラテンアメリカ
    • ラテンアメリカ：ギランバレー症候群市場、治療分野別、2019年～2032年
    • ラテンアメリカ：ギランバレー症候群市場、流通チャネル別、2019年～2032年
    • ラテンアメリカ：ギランバレー症候群市場、投与経路別、2019年～2032年
    • ギランバレー症候群市場- メキシコ
    • ギランバレー症候群市場- ブラジル
    • ギランバレー症候群市場- アルゼンチン

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/契約/展示会

第10章 企業プロファイル

  • Annexon Inc.
  • Bayer AG
  • Biotest AG
  • Cellenkos Inc
  • China Biologic Products Holdings Inc
  • CSL Limited
  • Grifols S A
  • Kedrion Biopharma Inc
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
図表

List of Tables

  • Table 1 Global Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 2 Global Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 3 Global Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 4 Guillain-Barre Syndrome Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 5 North America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 6 North America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 7 North America: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 8 U.S.: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 9 U.S.: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 10 U.S.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 11 Canada: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 12 Canada: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 13 Canada: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 14 Europe: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 15 Europe: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 16 Europe: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 17 UK: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 18 UK: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 19 UK: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 20 France: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 21 France: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 22 France: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 23 Germany: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 24 Germany: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 25 Germany: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 26 Italy: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 27 Italy: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 28 Italy: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 29 Spain: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 30 Spain: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 31 Spain: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 32 Netherlands: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 33 Netherlands: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 34 Netherlands: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 35 Russia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 36 Russia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 37 Russia: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 38 Asia Pacific: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 39 Asia Pacific: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 40 Asia Pacific: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 41 China: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 42 China: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 43 China: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 44 India: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 45 India: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 46 India: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 47 Malaysia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 48 Malaysia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 49 Malaysia: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 50 Japan: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 51 Japan: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 52 Japan: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 53 Indonesia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 54 Indonesia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 55 Indonesia: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 56 South Korea: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 57 South Korea: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 58 South Korea: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 59 Middle East & Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 60 Middle East & Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 61 Middle East & Africa: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 62 Saudi Arabia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 63 Saudi Arabia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 64 Saudi Arabia: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 65 UAE: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 66 UAE: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 67 UAE: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 68 Israel: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 69 Israel: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 70 Israel: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 71 South Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 72 South Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 73 South Africa: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 74 Latin America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 75 Latin America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 76 Latin America: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 77 Mexico: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 78 Mexico: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 79 Mexico: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 80 Brazil: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 81 Brazil: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 82 Brazil: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 83 Argentina: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • Table 84 Argentina: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 85 Argentina: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Guillain-Barre Syndrome Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Route of Administration
  • Figure 7. Global Guillain-Barre Syndrome Market, by Route of Administration, 2022 & 2032 (USD Million)
  • Figure 8. Market by Therapeutic Area
  • Figure 9. Global Guillain-Barre Syndrome Market, by Therapeutic Area, 2022 & 2032 (USD Million)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Guillain-Barre Syndrome Market, by Distribution Channel, 2022 & 2032 (USD Million)
  • Figure 12. Guillain-Barre Syndrome Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 13. Strategic Analysis - Guillain-Barre Syndrome Market
目次
Product Code: PM4787

The global guillain-barre syndrome market size is expected to reach USD 960.58 million by 2032, according to a new study by Polaris Market Research. The report "Guillain-Barre Syndrome Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, Others); By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The accelerated drug approval initiative by the United States Food and Drug Administration (USFDA) has played a pivotal role in fostering a significant rise in new product approvals within the pharmaceutical industry. This initiative aims to expedite the development and availability of innovative drugs, particularly those addressing unmet medical needs. By streamlining regulatory processes, the USFDA has created a more efficient pathway for pharmaceutical companies to bring novel treatments to market, ultimately benefiting patients with various medical conditions.

One notable area experiencing a surge in new product approvals is the market for Guillain-Barre Syndrome (GBS). GBS is a rare neurological disorder characterized by the immune system attacking the peripheral nerves, leading to muscle weakness and potentially severe complications. The heightened focus on accelerating drug approvals has spurred research and development efforts in the GBS space, resulting in the introduction of innovative therapies designed to address the unique challenges posed by this disorder.

Pharmaceutical companies are increasingly investing in GBS research, leveraging the streamlined regulatory processes to expedite clinical trials and bring potential treatments to market faster. This has not only broadened the therapeutic landscape for GBS patients but has also created a more competitive market environment, encouraging further innovation and advancements in treatment options.

The positive impact of the accelerated drug approval initiative is evident in the growing number of FDA-approved drugs for GBS, providing healthcare professionals with additional tools to manage and treat this challenging condition. As the pharmaceutical industry continues to embrace these expedited pathways, it holds the potential to transform the landscape of rare disease treatment, offering hope and improved outcomes for patients with conditions like Guillain-Barre Syndrome.

Guillain-Barre Syndrome Market Report Highlights

Intravenous immunoglobulin segment is anticipated to witness the highest growth in the coming years due to its ease of application.

Parental segment accounted for the largest market share owing to its effectiveness in intravenous immunoglobulin therapy.

Hospital Pharmacies segment is projected to experience a larger revenue share due to the growing number of auto-immune cases.

Asia Pacific will grow rapidly, attributable to the presence of a geriatric population, and innovations in the sector

The global players include Annexon, Bayer, Biotest, Cellenkos, China Biologic Products Holdings, CSL Limited, & Grifols.

Polaris Market Research has segmented the Guillain-Barre syndrome market report based on therapeutics, route of administration, distribution channel and region:

Guillain-Barre Syndrome, Therapeutics Outlook (Revenue - USD Million, 2019 - 2032)

  • Intravenous Immunoglobulin
  • Plasma Exchange
  • Others

Guillain-Barre Syndrome, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)

  • Oral
  • Parental

Guillain-Barre Syndrome, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Guillain-Barre Syndrome, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of APAC
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of MEA

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Guillain-Barre Syndrome Market Insights

  • 4.1. Guillain-Barre Syndrome Market - Distribution Channel Snapshot
  • 4.2. Guillain-Barre Syndrome Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of Guillain-Barre syndrome cases
      • 4.2.1.2. Increase in the risk of having Guillain-Barre syndrome
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Lower awareness about the treatment is likely to impede market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Guillain-Barre Syndrome Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Guillain-Barre Syndrome Market, by Therapeutic Area

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
  • 5.3. Intravenous Immunoglobulin
    • 5.3.1. Global Guillain-Barre Syndrome Market, by Intravenous Immunoglobulin, by Region, 2019-2032 (USD Million)
  • 5.4. Plasma Exchange
    • 5.4.1. Global Guillain-Barre Syndrome Market, by Plasma Exchange, by Region, 2019-2032 (USD Million)
  • 5.5. Others
    • 5.5.1. Global Guillain-Barre Syndrome Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Guillain-Barre Syndrome Market, by Route of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • 6.3. Oral
    • 6.3.1. Global Guillain-Barre Syndrome Market, by Oral, by Region, 2019-2032 (USD Million)
  • 6.4. Parental
    • 6.4.1. Global Guillain-Barre Syndrome Market, by Parental, by Region, 2019-2032 (USD Million)

7. Global Guillain-Barre Syndrome Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Guillain-Barre Syndrome Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Guillain-Barre Syndrome Market, by Retail Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.5. Others
    • 7.5.1. Global Guillain-Barre Syndrome Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Guillain-Barre Syndrome Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Guillain-Barre Syndrome Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Guillain-Barre Syndrome Market - North America
    • 8.3.1. North America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
    • 8.3.2. North America: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.3.3. North America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.3.4. Guillain-Barre Syndrome Market - U.S.
      • 8.3.4.1. U.S.: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.3.5. Guillain-Barre Syndrome Market - Canada
      • 8.3.5.1. Canada: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • 8.4. Guillain-Barre Syndrome Market - Europe
    • 8.4.1. Europe: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.3. Europe: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.4. Guillain-Barre Syndrome Market - UK
      • 8.4.4.1. UK: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.5. Guillain-Barre Syndrome Market - France
      • 8.4.5.1. France: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.5.3. France: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.6. Guillain-Barre Syndrome Market - Germany
      • 8.4.6.1. Germany: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.7. Guillain-Barre Syndrome Market - Italy
      • 8.4.7.1. Italy: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.8. Guillain-Barre Syndrome Market - Spain
      • 8.4.8.1. Spain: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.9. Guillain-Barre Syndrome Market - Netherlands
      • 8.4.9.1. Netherlands: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.4.10. Guillain-Barre Syndrome Market - Russia
      • 8.4.10.1. Russia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • 8.5. Guillain-Barre Syndrome Market - Asia Pacific
    • 8.5.1. Asia Pacific: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.5.4. Guillain-Barre Syndrome Market - China
      • 8.5.4.1. China: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.4.3. China: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.5.5. Guillain-Barre Syndrome Market - India
      • 8.5.5.1. India: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.5.3. India: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.5.6. Guillain-Barre Syndrome Market - Malaysia
      • 8.5.6.1. Malaysia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.5.7. Guillain-Barre Syndrome Market - Japan
      • 8.5.7.1. Japan: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.5.8. Guillain-Barre Syndrome Market - Indonesia
      • 8.5.8.1. Indonesia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.5.9. Guillain-Barre Syndrome Market - South Korea
      • 8.5.9.1. South Korea: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • 8.6. Guillain-Barre Syndrome Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.6.4. Guillain-Barre Syndrome Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.6.5. Guillain-Barre Syndrome Market - UAE
      • 8.6.5.1. UAE: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.6.6. Guillain-Barre Syndrome Market - Israel
      • 8.6.6.1. Israel: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.6.7. Guillain-Barre Syndrome Market - South Africa
      • 8.6.7.1. South Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
  • 8.7. Guillain-Barre Syndrome Market - Latin America
    • 8.7.1. Latin America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.7.4. Guillain-Barre Syndrome Market - Mexico
      • 8.7.4.1. Mexico: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.7.5. Guillain-Barre Syndrome Market - Brazil
      • 8.7.5.1. Brazil: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
    • 8.7.6. Guillain-Barre Syndrome Market - Argentina
      • 8.7.6.1. Argentina: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Annexon Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Bayer AG
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Biotest AG
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Cellenkos Inc
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. China Biologic Products Holdings Inc
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. CSL Limited
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Grifols S A
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Kedrion Biopharma Inc
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Octapharma AG
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Takeda Pharmaceutical Company Limited
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development